Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cetuximab plus S-1 and irinotecan (IRIS) as first-line treatment in RAS wild type metastatic colorectal cancer, a phase I/II trial (KSCC1401)

ABSTRACT: Interventions: Phase I: IRIS + cetuximab S-1 80-120mg day1-14 Irinotecan 120-150mg/m2 day1 Cetuximab 250mg/m2 day1,8,15 (initial dose:400mg/m2) administered every 3 weeks until PD Phase II: IRIS + cetuximab Administered the RD fixed in Phase I Primary outcome(s): Phase I: maximum tolerated dose (MTD) and recommended dose (RD) Phase II: objective response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631161 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 and 8 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 80mg/m2, day1,8 Primary outcome(s): 1) Phase I study To determine the maximum tolerated dose (MTD) and recommended dose (RD) 2) Phase II study Response rate Study Design: Single arm Non-randomized

| 2618747 | ecrin-mdr-crc

Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: Cetuximab 400mg/m2 Day1, 250mg/m2 Day 8, 15 Irinotecan 100-150mg/m2/Day1 S-1 80-120mg/day Day1-14 Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

| 2626021 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Randomized phase II trial of Hange-shasin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS+Bev second-line treatment

Project description:Interventions: S-1+CPT-11+bevacizumab+Placebo S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Placebo day1-28 q4w S-1+CPT-11+bevacizumab+hange-shashin-to S-1 80-120mg/day day1-14 q4w CPT-11 100mg/m2 day1,15 q4w Bevacizumab 5mg/kg day1, 15 q4w Hange-shashin-to 7.5g/day day1-28 q4w Primary outcome(s): Incidence of grade 3 or more diarrhea until the end of 3rd cycle Study Design: Parallel Randomized

| 2627635 | ecrin-mdr-crc

Iris

Project description:Iris sp. overview

| PRJNA1145549 | ENA

Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).

Project description:Interventions: Cetuximab/S-1 combination therapy Cetuximab weekly administration 400 mg/m2(day1), 250mg/m2/week(except day1) S-1 80-120mg/day, PO from day1 to day 28 of each 42 day cycle. Primary outcome(s): Progression free survival(PFS) Study Design: Single arm Non-randomized

| 2617952 | ecrin-mdr-crc

De novo Assembly of Royal Iris (Iris atropurpurea, section Oncocyclus) transcriptome

Project description:Transcriptome sequencing of non-model organisms is valuable resource of the genetic basis of ecological-meaningful traits. The Royal Irises, Iris section Oncocyclus (Iris: Iridaceae, order Asparagales), are a Middle-East group of species in the course of speciation. The species are characterized with extremely large flowers, a huge range of flower colors and a unique pollination system. The Royal Irises, which are a symbol of conservation in the Middle-east, serve as a model for evolutionary processes of speciation and plant ecology. However, there are not sufficient transcriptomic and genomic data for molecular characterization. Thus, it is necessary to generate massive transcript sequences for functional characterization and molecular marker development for the Royal Irises. The Iris transcriptome sequencing provides valuable resource for studying adaptation-associated traits in this non-model plant. Although intensive eco-evolutionary studies, this is the first reported transcriptome for the Royal Irises. The data available from this study will facilitate gene discovery, functional genomic studies and development of molecular markers in irises, and will provide genetic tools for their conservation.

2021-08-18 | GSE121786 | GEO

Iris virginica

Project description:Iris virginica

| PRJNA807620 | ENA

Lamprotornis iris

Project description:Lamprotornis iris

| PRJNA960032 | ENA

Lepidothrix iris

Project description:Lepidothrix iris

| PRJNA960162 | ENA